InsidersTradesSigma
Total declarations
Company
▲ Purchases (8 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
8
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-23.9%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by KIM PETER S, Director. Director active across 1 company, notably Entrada Therapeutics, Inc.. In total, 9 disclosures have been logged. Split: 8 buys · 0 sell. Total volume traded: €1.1m. Activity tracked since 19 March 2024. The latest transaction was filed on 13 May 2024 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations9 total
25,000 shares@ US$14.68040.14% mcap50.0% of flowCommon StockSEC:0001689375-25-000035:0
Canonical exit: 11 Aug 2024 (T+90)
25,000 shares@ US$14.680450.0% of flowCommon StockSEC:0001689375-25-000035
Canonical exit: 11 Aug 2024 (T+90)
11,918 shares@ US$6.065.5% of flowCommon StockSEC:0001689375-24-000032:0
25,000 shares@ US$14.586927.8% of flowCommon StockSEC:0001689375-24-000029:0
Canonical exit: 12 Aug 2024 (T+90)
2,276 shares@ US$14.04422.4% of flowCommon StockSEC:0001689375-24-000028:0
Canonical exit: 6 Aug 2024 (T+90)
2,600 shares@ US$13.5732.7% of flowCommon StockSEC:0001689375-24-000021:0
Canonical exit: 7 Jul 2024 (T+90)
1,512 shares@ US$13.75261.6% of flowCommon StockSEC:0001689375-24-000020:0
Canonical exit: 26 Jun 2024 (T+90)
3,118 shares@ US$13.7593.3% of flowCommon StockSEC:0001689375-24-000019:0
Canonical exit: 20 Jun 2024 (T+90)
900 shares@ US$12.66330.9% of flowCommon StockSEC:0001689375-24-000018:0
Canonical exit: 17 Jun 2024 (T+90)
9 of 9 declarations
About KIM PETER S
Kim Peter S is a Director at Entrada Therapeutics, Inc., an innovative company in the biotechnology field. As a board member, he contributes to shaping strategy and overseeing the company's performance. Peter brings valuable expertise in biotechnology, thus supporting Entrada's mission.
